Elizabeth Brigham

West Virginia University — United States

Medicine · Health Sciences

18h-index2.4kcitations43works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(18), Neuroscience and Neuropharmacology Research(6), Computational Drug Discovery Methods(6), Cholinesterase and Neurodegenerative Diseases(6), Parkinson's Disease Mechanisms and Treatments(5)

Publications43 total

Reconsidering Pediatric Critical Care Sequencing: A Qualitative Exploration of Postgraduate Year 1 PICU Rotations Among Senior Pediatric Residents
Pediatric Critical Care Medicine·2026
Improving pediatric trauma care at a level 1 pediatric trauma center through the multi-year implementation of a Pediatric Trauma Boot Camp curriculum
Advances in Simulation·2025Open Access
1105: RESIDENT PERCEPTIONS OF PGY-1 PEDIATRIC CRITICAL CARE ROTATIONS
Critical Care Medicine·2025
741: PEDIATRIC TRAUMA BOOT CAMP: UTILIZING INTERDISCIPLINARY EDUCATION TO IMPROVE PEDIATRIC TRAUMA CARE
Critical Care Medicine·2022
860: FELLOW-LED PROCEDURE CURRICULUM FOR PEDIATRIC RESIDENTS IN THE PEDIATRIC INTENSIVE CARE UNIT
Critical Care Medicine·2022
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
Journal of Pharmacology and Experimental Therapeutics·2018· 24 citedOpen Access
Pharmacokinetic/Pharmacodynamic Analysis of Amantadine for Levodopa-Induced Dyskinesia: Correlation of Therapeutic Plasma Concentrations from Multiple Species with Humans (S45.006)
Neurology·2018· 1 cited
Extended-release (ER) formulations of aminoadamantanes as NMDA-receptor antagonists: pharmacokinetic (PK) determinants of improved tolerability (P5.064)
Neurology·2018
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
Neurobiology of Disease·2015· 41 citedOpen Access
P1–010: Chronic treatment with scyllo‐inositol reduces brain myo‐inositol levels and enhances performance in a rat model of social withdrawal
Alzheimer s & Dementia·2013Open Access
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
PLoS ONE·2013· 90 citedOpen Access
Discovery of (<i>R</i>)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND006) and (<i>R</i>)-4-Cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2<i>H</i>-pyrazolo[4,3-<i>c</i>]quinoline (ELND007): Metabolically Stable γ-Secretase Inhibitors that Selectively Inhibit the Production of Amyloid-β over Notch
Journal of Medicinal Chemistry·2013· 32 cited
Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 33 citedOpen Access
The beta-secretase-derived C-terminal fragment of APP (C99): a key determinant for intraneuronal pathology in the 3xTgAD mouse
Molecular Neurodegeneration·2013· 1 citedOpen Access
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 11 citedOpen Access
The β-Secretase-Derived C-Terminal Fragment of βAPP, C99, But Not Aβ, Is a Key Contributor to Early Intraneuronal Lesions in Triple-Transgenic Mouse Hippocampus
Journal of Neuroscience·2012· 191 citedOpen Access
Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies
Drug Delivery·2012· 17 cited
Design, synthesis and structure–activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors
Bioorganic & Medicinal Chemistry Letters·2011· 9 citedOpen Access
P4‐022: Neuropathology associated with administration of a nonselective beta secretase (BACE) and cathepsin D inhibitor in Mdr 1a/b knockout mice
Alzheimer s & Dementia·2011· 1 cited
P2‐021: Variable effects of the gamma‐secretase inhibitor ELND006 on Aβ across different compartments (brain, ISF, CSF, and plasma) following sustained exposure via subcutaneous osmotic pumps in wild‐type mice
Alzheimer s & Dementia·2011
page 1 of 3Next →

Frequent Co-authors

Erich Goldbach(22), Hing L. Sham(15), Guriqbal S. Basi(14), Andrei W. Konradi(14), John‐Michael Sauer(14), Albert W. Garofalo(12), Daniel Ness(11), Michael P. Bova(11), Gary D. Probst(11), Ruth Motter(10), Danielle L. Aubele(9), Martin L. Neitzel(9), Anh P. Truong(9), Kevin P. Quinn(9), Kevin P. Quinn(8), William H. Wallace(8), Pamela Santiago(7), Susanna S. Hemphill(7), Darren Dressen(7), Grace Kwong(7)